Search Results
Your search for AT matches 28883 pages
Showing 3301 - 3350Loss of Y Chromosome in Men and Bladder Cancer Progression
Researchers have found that the loss of the Y chromosome, a common impact of the aging process in men, may help cancer cells evade the body’s immune system and result in aggressive bladder cancer—but it may also render the disease more vulnerable and responsive to immune checkpoint...
DIPLOMA Trial: Minimally Invasive Distal Pancreatectomy Noninferior to Open Surgery for Early-Stage Pancreatic Cancer
For patients with fully resectable pancreatic cancer, a minimally invasive surgical approach—laparoscopic or robotic—was shown to be comparable to open distal pancreatectomy in the multicenter randomized phase III DIPLOMA trial. These results were presented at the 2023 ASCO Annual Meeting and at a...
MIRASOL Trial: First Targeted Therapy for Platinum-Resistant Ovarian Cancer to Improve Survival Outcomes
Mirvetuximab soravtansine-gynx, a novel antibody-drug conjugate, significantly improved progression-free and overall survival in patients with platinum-resistant, recurrent ovarian cancers that express high levels of folate receptor–alpha (FR-alpha), according to the results of the phase III...
Prostate Cancer Disparities and the ‘Last Mile’ Problem
Prostate cancer is the most commonly diagnosed cancer in men in the United States and the second-leading cause of cancer death.1 It also offers a sobering example in the national conversation on racial disparities in cancer care. Despite a deeper scientific understanding of the disease—as well as ...
Expert Point of View: Rita Nanda, MD
“I expect the NATALEE trial results will change clinical practice,” stated ASCO expert Rita Nanda, MD, Director of the Breast Oncology Program at University of Chicago Medicine. “Three different CDK4/6 inhibitors have all been shown to improve progression-free survival in the first- and second-line ...
Adjuvant Treatment With Ribociclib Reduces Risk of Recurrence in Hormone Receptor–Positive, HER2-Negative, Early-Stage Breast Cancer
The addition of the CDK4/6 inhibitor ribociclib to endocrine therapy significantly improved invasive disease–free survival in women with hormone receptor–positive, HER2-negative, early-stage breast cancer. These results of the phase III NATALEE trial were reported by lead author Dennis J. Slamon,...
Expert Point of View: Rimas Vincas Lukas, MD
Rimas Vincas Lukas, MD, of Northwestern University, was the formal discussant of this plenary session abstract on the INDIGO trial findings. “Because of its slowly progressive nature, glioma is insidious. The impact of the disease and its treatments has important consequences for patients,...
INDIGO Trial: IDH Inhibitor Improves Progression-Free Survival in Grade 2 IDH1/2-Mutated Gliomas
The oral IDH1/2 inhibitor vorasidenib significantly improved progression-free survival in patients with grade 2 gliomas expressing IDH1/2 mutations in the phase III INDIGO trial. These results, which were reported by lead author Ingo K. Mellinghoff, MD, FACP, of Memorial Sloan Kettering Cancer...
Surgeon Quality Metrics and Survival After Curative-Intent Surgery for NSCLC
In a study reported in the Journal of Clinical Oncology, Ray et al found that higher surgeon quality (determined by intermediate outcome metrics) was associated with improved overall survival among patients undergoing curative resection for non–small cell lung cancer (NSCLC). The investigators...
First-Line Nivolumab/Ipilimumab Followed by Nivolumab in a Clinically Diverse Population With Unresectable Stage III or IV Melanoma
In the phase IIIb CheckMate 401 trial reported in the Journal of Clinical Oncology, Reinhard Dummer, MD, and colleagues described outcomes with first-line nivolumab/ipilimumab followed by nivolumab in a clinically diverse population of patients with unresectable stage III or IV melanoma, including...
FDA Approves Talazoparib With Enzalutamide for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
On June 20, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna) with enzalutamide for homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer. TALAPRO-2 Efficacy was evaluated in TALAPRO-2 (ClinicalTrials.gov identifier...
Cancer Disparities Potentially Responsible for Higher Incidence and Mortality Rates in Appalachian Kentucky
Investigators have shed light on the disparities that may be contributing to the high cancer burden of Appalachian Kentucky compared with the rest of the state and country, according to a new study published by Hudson et al in The Journal of Rural Health. Kentucky currently ranks first in the...
FDA Launches Pilot Program to Help Reduce Risks Associated With Using Laboratory Developed Tests to Identify Cancer Biomarkers
The U.S. Food and Drug Administration (FDA) announced a new voluntary pilot program to help physicians select safe and effective cancer treatments, with guidance on in vitro companion diagnostic tests to determine which corresponding oncology drugs may provide the most benefit for their patients....
Late-Onset Memory Impairment in Adult Survivors of Childhood Cancer
In an analysis reported in JAMA Network Open, Phillips et al found that adult survivors of childhood cancer were at an increased risk of new-onset memory impairment vs their siblings. Modifiable factors associated with increased risk of impairment among survivors were identified. Study Details The...
Adjuvant Cisplatin/Gemcitabine vs Cisplatin/Fluorouracil After Chemoradiotherapy for Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that adjuvant cisplatin/gemcitabine improved progression-free survival vs cisplatin/fluorouracil following chemoradiotherapy in previously untreated patients with N2 or N3 nasopharyngeal carcinoma. Study Details In the...
Adagrasib Shows Activity in Patients With KRAS G12C–Mutated NSCLC and Untreated Brain Metastases
The KRAS G12C inhibitor adagrasib may be effective at suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to a new study published by Negrao et al in the Journal of Clinical Oncology....
Patients With Refractory Metastatic Colorectal Cancer May Experience Survival Benefits With Fruquintinib
Targeted therapy with fruquintinib may improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer, according to a novel study published by Dasari et al in The Lancet. Background According to the American Cancer Society, colorectal cancer is the...
Aromatase Inhibitors May Limit Effectiveness of Weight Loss Medications in Breast Cancer Survivors
Aromatase inhibitors may interfere with the efficacy of weight loss medications in breast cancer survivors, according to a new study presented by Fansa et al at the 2023 Endocrine Society Annual Meeting. Background Aromatase inhibitors are designed to block the activity of the aromatase enzyme,...
Older Breast Cancer Survivors May Experience Accelerated Aging, Worse Functional Outcomes Following Chemotherapy
Investigators have found that older breast cancer survivors—particularly those exposed to chemotherapy—may experience greater epigenetic aging and poorer outcomes than those without a history of cancer, according to a new study published by Rentscher et al in Cancer. Background Epigenetic aging...
Patient-Reported Outcomes From the PROSPECT Trial: Neoadjuvant FOLFOX vs Chemoradiation for Locally Advanced Rectal Cancer
In an analysis from the PROSPECT trial (Alliance N1048) reported in the Journal of Clinical Oncology, Ethan Basch, MD, MSc, FASCO, and colleagues identified patient-reported outcome patterns among those receiving neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin) or pelvic chemoradiation...
Longitudinal ctDNA Methylation Status and Risk of Recurrence After Surgery in Patients With Stage I to III Colorectal Cancer
In a Chinese study reported in JAMA Oncology, Mo et al found that longitudinal measurement of circulating tumor DNA (ctDNA) methylation permitted early detection of disease recurrence in patients undergoing surgery for stage I to III colorectal cancer. Study Details In the prospective cohort...
FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed or Refractory DLBCL
On June 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma,...
Encorafenib and Binimetinib in BRAF V600E–Mutant Metastatic NSCLC
In the phase II PHAROS trial reported in the Journal of Clinical Oncology, Gregory J. Riely, MD, PhD, and colleagues found that the combination of encorafenib and binimetinib showed activity in both treatment-naive and previously treated patients with BRAF V600E–mutant metastatic non–small cell...
Impact of Historic Redlining Practices on Cancer Screening Rates
Although redlining was outlawed more than 50 years ago, individuals who currently live in historically redlined areas may be less likely to be screened for breast cancer, colorectal cancer, and cervical cancer than individuals who live in areas not associated with redlining practices, according to...
Study Evaluates Clinical Utility of Novel Liquid Biopsy-Breast Cancer Methylation Prototype Assay
A novel, automated liquid biopsy test—the Liquid Biopsy for Breast Cancer Methylation assay—may be effective at predicting early disease progression and potential survival outcomes in patients with metastatic breast cancer after as little as 1 month of treatment, according to a study published by...
Research Sheds Light on the Evolution of Precursor Conditions to Multiple Myeloma
Researchers have shared novel insights into the evolution of multiple myeloma from precursor disease, which may help physicians better identify patients whose disease is likely to progress as well as develop new interventions, according to a recent study published by Dang et al in Cancer Cell. How...
Alectinib May Be More Effective When Taken With Larger Meals in Some Patients With NSCLC
Researchers have found that when the small molecule kinase inhibitor alectinib was taken in combination with a fuller breakfast or lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast in patients with non–small cell lung cancer (NSCLC), according...
S-1 Chemoradiotherapy for Older Patients With Inoperable Esophageal Squamous Cell Carcinoma
In a Chinese phase III trial reported in JAMA Network Open, Wang et al found that oral S-1 chemotherapy given with simultaneous integrated boost radiotherapy (SIB-RT) and following SIB-RT improved overall survival in patients aged 70 or older with inoperable esophageal squamous cell carcinoma....
Adagrasib in Treatment of KRAS G12C–Mutated Advanced Solid Tumors
As reported in the Journal of Clinical Oncology by Tanios S. Bekaii-Saab, MD, and colleagues, findings in the phase II cohort of the KRYSTAL-1 trial showed activity of adagrasib in patients with KRAS G12C–mutated advanced solid tumors. As noted by the investigators, the KRAS G12C inhibitor...
Perioperative Palliative Care and Health-Related Quality of Life in Patients Undergoing Curative-Intent Surgery for Upper Gastrointestinal Cancers
In a study reported in JAMA Network Open, Aslakson et al found that perioperative surgeon/palliative care team co-management did not improve health-related quality of life vs surgeon team management alone in patients undergoing curative-intent surgery for upper gastrointestinal cancers. Study...
Mortality Rates From Second Cancers in Hispanic and Non-Hispanic Black Breast Cancer Survivors
Hispanic and non-Hispanic Black breast cancer survivors may experience higher rates of mortality after being diagnosed with a second primary cancer than breast cancer survivors of other ethnic and racial groups, according to a new study published by Deng et al in the Journal of the National Cancer...
Impact of MCCPDC Prices of Generic Oncology Drugs on Medicare Beneficiaries
Medicare beneficiaries could save between $228.1 million and $2.15 billion per year if insurers operating the U.S. government's Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company (MCCPDC), according to a new study...
Preoperative Stereotactic Radiosurgery May Help Patients With Metastatic Brain Tumors Reduce the Risk of Disease Progression and Adverse Effects
Researchers have found that preoperative stereotactic radiosurgery is associated with low rates of tumor recurrence, adverse radiation effects, and meningeal disease in patients with metastatic brain tumors, according to a novel study published by Prabhu et al in JAMA Oncology. Background As...
Risk Factors for Primary Bone Cancer in Childhood Cancer Survivors: Bone Tissue Radiation Exposure and Alkylating Agent Dose
In a case-control study reported in the Journal of Clinical Oncology, Reulen et al found that an increased risk of primary bone cancer was associated with increasing radiation dose to bone tissue and increasing alkylating agent dose among survivors of childhood cancer. As noted by the...
Noncovalent BTK Inhibitor Pirtobrutinib in Patients With Mantle Cell Lymphoma Previously Treated With Covalent BTK Inhibitors
In the phase I/II BRUIN trial reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with mantle cell lymphoma who were previously treated...
Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding
Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequently in other racial and ethnic groups, according to a new study published by Haghighat et al in the...
Personalized mRNA Vaccines May Transform the Treatment of Melanoma
The rates of survival and disease recurrence improved significantly when a personalized mRNA vaccine tailored to the patients’ tumor genetics was coupled with immunotherapy in those who had undergone surgery for high-risk melanoma, according to novel findings presented by Khattak et al at the 2023...
Exposure to Ultraviolet Radiation May Propel Transformation of BPDCN Cells to Leukemia in the Skin
For some precancerous cells, traveling from the bone marrow to the skin can trigger genetic transformations that can result in leukemia, according to a novel study published by Griffin et al in Nature. The new findings may have shed light on what researchers have termed the “genetic travelogue” of...
Factors Associated With Nonadherence to Lung Cancer Screening Recommendations
In a single-institution retrospective cohort study reported in JAMA Network Open, Lin et al identified factors associated with nonadherence to lung cancer screening recommendations among patients undergoing screening—and found that negative findings on two successive screenings were associated with ...
Fecal Microbiota Transplantation: Its Role for Patients Undergoing Allogeneic HCT and Receiving Induction Therapy for AML
In a single-institution phase II study reported in the Journal of Clinical Oncology, Rashidi et al found that fecal microbiota transplantation (FMT) did not reduce the risk of infection in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) or patients with acute myeloid...
Accumulation of Chronic Comorbidities Among Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Esbenshade et al found that survivors of childhood cancer were more likely to accumulate comorbidities over time than their siblings or the general population. Study Details In the study, Cumulative Illness Rating Scale for Geriatrics...
Study Finds Preoperative MRI Does Not Significantly Impact Margin Status in Patients With Breast Cancer
The use of preoperative magnetic resonance imaging (MRI) did not significantly reduce positive margins after breast-conserving surgery, according to data presented during a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Although MRI has been shown to detect...
New Data May Inform Treatment of Pregnant Patients With Relapsed or Refractory Lymphoma
In a new study reported by Farooq et al in Blood Advances, patients with relapsed or refractory lymphoma during pregnancy had a progression-free survival rate of 24% and an overall survival rate of 83%. Background Receiving a lymphoma diagnosis during pregnancy may be uncommon but can occur for...
Patients With Lymphoma Who Have Depression or Anxiety May Experience Worse Survival Outcomes
Investigators have found that patients who had depression and/or anxiety prior to their diagnosis of diffuse large B-cell lymphoma (DLBCL) may have had shorter survival times than patients who didn’t have a mental health condition prior to their DLBCL diagnosis, according to a new study published...
NCI’s ComboMATCH Initiative Will Evaluate New Drug Combinations Guided by Tumor Biology
The National Cancer Institute (NCI) has launched a new set of large, precision medicine–based clinical trials—known as the ComboMATCH initiative—that will examine the efficacy of novel drug combinations targeting specific tumor mutations in adult and pediatric patients with cancer. The new...
Risk of Dementia and Mortality With BCG Vaccine in Non–Muscle-Invasive Bladder Cancer
In a study reported in JAMA Network Open, Weinberg et al found that receipt of the bacillus Calmette-Guérin (BCG) vaccine in patients with non–muscle-invasive bladder cancer was associated with a lower risk of Alzheimer’s disease and related dementias—as well as a lower risk of mortality—compared...
Early Detection of Pancreatic Cancer Saved My Life
When my sister was diagnosed with breast cancer 25 years ago, her medical team suggested we undergo genetic testing for the BRCA gene mutation. I knew that being a BRCA carrier put me at greater risk for breast and ovarian cancers, but I had no idea it also increased my risk for pancreatic cancer....
Tak W. Mak, PhD, FAACR, Selected for 2023 Pezcoller Foundation–AACR International Award for Achievement in Cancer Research
Tak W. Mak, PhD, FAACR, was recently announced as this year’s winner of the Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research. Dr. Mak is Senior Scientist at the Princess Margaret Cancer Centre, University...
Polatuzumab Vedotin-piiq for Previously Untreated DLBCL–Not Otherwise Specified and High-Grade B-Cell Lymphoma
On April 19, 2023, polatuzumab vedotin-piiq was approved for use with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with diffuse large B-cell lymphoma (DLBCL)–not otherwise specified or those with high-grade B-cell lymphoma who have an International...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
